CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $14,711,731 | +17.6% | 225,118 | +9.4% | 0.03% | +26.1% |
| Q2 2022 | $12,508,448 | +6.0% | 205,840 | +9.5% | 0.02% | +35.3% |
| Q1 2022 | $11,802,008 | +113.6% | 188,020 | +157.9% | 0.02% | +21.4% |
| Q4 2021 | $5,525,000 | -31.5% | 72,909 | +1.2% | 0.01% | -39.1% |
| Q3 2021 | $8,063,000 | -58.6% | 72,037 | -40.1% | 0.02% | -17.9% |
| Q2 2021 | $19,484,000 | +2184.2% | 120,352 | +1619.3% | 0.03% | +833.3% |
| Q1 2021 | $853,000 | +277.4% | 7,000 | +37.3% | 0.00% | +200.0% |
| Q3 2018 | $226,000 | -24.7% | 5,100 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $300,000 | – | 5,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |